(Q34186242)

31 July 2017

1 reference

title

Novel melatonin-based therapies: potential advances in the treatment of major depression (English)

1 reference

31 July 2017

0 references

Naomi L Rogers

0 references

Ian B Hickie

1 reference

31 July 2017

language of work or name

English

0 references

publication date

17 May 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

378

1 reference

31 July 2017

issue

9791

1 reference

31 July 2017

page(s)

621-631

1 reference

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Is depression overdiagnosed? No.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The circadian basis of mood disorders: recent developments and treatment implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Circadian rhythm disturbances in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Interaction of chronic sleep restriction and circadian system in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Circadian genes and bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

New insights into the mammalian circadian clock.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Entrainment of the human circadian system by light

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Hypersomnia across mood disorders: a review and synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Sleep complaints and depression in an aging cohort: A prospective perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Circadian genes, rhythms and the biology of mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Interpersonal and social rhythm therapy: a means of improving depression and preventing relapse in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Drug effects on REM sleep and on endogenous depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Promoting adjustment of the sleep-wake cycle by chronobiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

From the basic neuroscience of circadian clock function to light therapy for depression: on the emergence of chronotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Melatonin and Melatonin Analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Rhythms and the pharmacology of lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Effect of Lithium Carbonate on Circadian Periodicity in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Molecular effects of lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

A role for glycogen synthase kinase-3beta in the mammalian circadian clock

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Chronotherapeutics (light and wake therapy) in affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Impact of sleep debt on metabolic and endocrine function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The Efficacy of Light Therapy in the Treatment of Mood Disorders: A Review and Meta-Analysis of the Evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Light therapy for non-seasonal depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Efficacy of light therapy in nonseasonal depression: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The pattern of melatonin receptor expression in the brain may influence antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Mammalian melatonin receptors: molecular biology and signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Negative effects of melatonin on depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Pathophysiology of depression: role of sleep and the melatonergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The effects of ramelteon in a first-night model of transient insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Agomelatine, a melatonin agonist with antidepressant properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Agomelatine: a preliminary review of a new antidepressant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

The pharmacological properties of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960095-0

7 January 2021

10.1016/S0140-6736(11)60095-0

Identifiers

DOI

1 reference

31 July 2017

1 reference